item management s discussion and analysis of financial condition and results of operations this discussion contains forward looking statements which are subject to certain risks and uncertainties that can cause actual results to differ materially from those described 
factors that may cause such differences include but are not limited to those described in the section entitled risk factors 
readers are cautioned not to place undue reliance on these forward looking statements which speak only as of the date hereof 
the company undertakes no obligation to publicly update or revise these forward looking statements to reflect events or circumstances after the date hereof 
the company is engaged in the discovery  development and commercialization of novel  small molecule pharmaceuticals for the treatment of major diseases for which there are currently limited or no effective treatments 
the company is a leader in the use of structure based drug design  an approach to drug discovery that integrates advanced biology  biophysics  chemistry and information technologies 
the company is conducting research and development programs to develop pharmaceuticals for the treatment of viral diseases  multidrug resistance in cancer  autoimmune and inflammatory diseases and neurodegenerative disorders 
to date  the company has not received any material revenues from the sale of pharmaceutical products 
a new drug application nda was submitted in october for the company s lead product  agenerase tm amprenavir for the treatment of hiv infection 
glaxo wellcome plc glaxo wellcome  vertex s partner  has also submitted applications for market approval to canadian and european regulatory agencies 
assuming the nda is approved  the company will receive a royalty on sales of agenerase from glaxo wellcome 
the company has incurred operating losses since its inception and expects to incur a loss in the company believes that operating losses may continue beyond  even if significant royalties are realized on agenerase tm sales  because the company is planning to make significant investments in research and development for its other potential products 
the company expects that losses will fluctuate from quarter to quarter and that such fluctuations may be substantial 
results of operations year ended december  compared with year ended december  the company s total revenues were  in as compared to  in in  revenues consisted of  under the company s collaborative agreements   in investment income and  in government grants and other income 
collaborative revenue in included a  payment from schering ag  germany schering ag associated with the signing of a collaborative agreement for the company s neurophilin ligand program and  of research funding under that agreement  a  milestone payment from kissei pharmaceutical co  ltd 
kissei for the acceptance of vx as the lead development candidate for the company s p map kinase program  and a  milestone payment from glaxo wellcome for the nda filing for agenerase 
other collaborative revenue in included  from kissei   from glaxo wellcome   from eli lilly and company lilly and  from others 
research funding requirements under the glaxo wellcome agreement ended on december   although glaxo wellcome continues to have certain development funding obligations 
in  revenues consisted of  under the company s collaborative agreements   in investment income  and  in government grants and other income 
revenue from collaborative agreements in consisted of  from glaxo wellcome   from hoechst marion roussel hmr   from kissei   from page lilly and  from others 
total costs and expenses increased to  in from  in research and development expenses increased to  in from  in the company increased research staffing  including opening a research site in the uk  to fully staff a higher number of discovery programs 
in addition  the company expanded its development infrastructure 
general and administrative expenses increased in to  from  in primarily as a result of headcount growth to handle the administrative requirements of the company s growing research and development operation  legal expenses associated with expansion of the company s intellectual property position and marketing expenses associated with the anticipated launch of agenerase and the company s co promotion preparations 
interest expense increased in to  from  in due to higher levels of equipment financing during the company recorded a net loss of  or per share in compared to a net loss of  or per share in year ended december  compared with year ended december  the company s total revenues increased to  in from  in in  revenues consisted of  under the company s collaborative agreements   in investment income  and  in government grants and other income 
the principal reasons for the increase in revenue in were the commencement of new collaborations with lilly on the company s hepatitis c protease program and with kissei on the company s p map kinase program  in addition to greater investment income from higher levels of cash and investments 
the collaborations with lilly and kissei included payments of  and  respectively  and research funding of  and  respectively 
other collaborative revenue in included  from kissei   from hmr  which included a  milestone payment   from glaxo wellcome  and  from others 
research funding requirements under the hmr agreement ended on december   although hmr continues to have certain development funding obligations 
in  revenues consisted of  under the company s collaborative agreements   in investment income and  in government grants and other income 
revenue from collaborative agreements consisted of  from glaxo wellcome   from hmr   from kissei and  from others 
the company s total costs and expenses increased to  in from  in in  the company paid  to obtain a non exclusive  world wide license under certain gd searle co 
searle patent applications claiming hiv protease inhibitors 
research and development expenses increased to  in from  in principally due to the commencement of preclinical development activities for drug candidates in the ice and impdh programs as well as the continued expansion of the company s core scientific staff 
in addition  general and administrative expenses increased to  in from  in the increase in general and administrative expense principally reflects the impact of personnel additions  an increase in legal expenses related to patent activity and an increase in marketing activities 
interest expense increased to  in from  in due to higher levels of equipment lease financing during the year 
the company recorded a net loss of  or per share in compared to a net loss of  or per share in the lower loss per share reflects not only a lower aggregate loss but also an increase in average common shares outstanding from  in to  in due to two common stock offerings in august and march page liquidity and capital resources the company s operations have been funded principally through strategic collaborative agreements  public offerings and private placements of the company s equity securities  equipment financing  government grants and investment income 
assuming agenerase is approved by the fda  the company will begin receiving product royalty revenue in the company has been expanding its operations in order to increase and advance the number of potential products in its research and development pipeline 
consequently  the company expects to incur increased research and development and related supporting expenses and is likely to continue experiencing losses on a quarterly and annual basis 
the company also expects to incur substantial administrative and commercialization expenditures in the future and additional expenses related to the filing  prosecution  defense and enforcement of patent and other intellectual property rights 
the company expects to finance these substantial cash needs with expected royalty revenue from agenerase  its existing cash and investments of approximately  at december   together with investment income earned thereon  future payments under its existing collaborative agreements  and facilities and equipment financing 
to the extent that funds from these sources are not sufficient to fund the company s activities  it will be necessary to raise additional funds through public offerings or private placements of securities  or new research collaborations for new or existing projects or other methods of financing 
there can be no assurance that such financing will be available on acceptable terms  if at all 
the company s aggregate cash and investments decreased by  during to  at december  cash used by operations  principally to fund research and development activities  was  during the same period 
the company also expended  during this period to acquire property and equipment  principally for research equipment and facilities 
during  the company entered into equipment financing arrangements in the aggregate amount of  and repaid  of its lease obligations 
in addition to the expansion of the research and development activities in the us  the company expanded its us operations to include a research site during the company expects that  in general  research and development as well as general and administrative expenses will continue to increase as the company starts new research projects  advances current clinical and preclinical candidates  and expands its marketing and business development activities 
during  the company and schering ag entered into a collaborative agreement to research  develop and commercialize novel  orally active neurophilin ligand compounds to promote nerve regeneration for the treatment of a number of neurological diseases 
under the terms of the agreement  schering ag will pay the company up to  composed of a  license payment paid in september   of product research funding over five years and potentially  of development and commercialization milestone payments 
at december   the company leased approximately  square feet of office and research space in the us and  square feet in the us these leases have terms ranging from to years 
in addition  the company s liability for capitalized equipment lease obligations and other equipment financing totaled approximately million at december  year the company has completed its evaluation of its business critical information technology systems it systems and has determined the actions necessary in order to ensure that such it systems will be able to function without disruption with respect to the application of dating systems in the year the company has begun to upgrade  replace and test certain of its it page systems based on the results of that evaluation 
evaluation of embedded systems in the company s non computer equipment non it systems for year compliance is under way but has not been completed 
in addition to risks associated with the company s own computer systems and equipment  the company has relationships with  and is to varying degrees dependent upon  a number of third parties that provide goods  services and information to the company 
these include contract manufacturers  suppliers  licensees and licensors  vendors  research partners and financial institutions  whose systems and equipment are outside the control of the company 
if certain of these third parties experience failures in their computer systems or equipment due to year non compliance  it could affect the company s ability to engage in normal business activities 
the company intends to contact its significant vendors and partners to ascertain their year compliance and to determine the extent to which the company is vulnerable to their non compliance  if any 
the company expects to complete its internal evaluation and remediation efforts and its assessment of third party compliance and contingency plans by mid however  there can be no assurance that these evaluations and any required remedial actions will be able to be completed on a timely basis 
the company believes that its it systems and non it systems are either already year compliant or will be so prior to the year the company estimates the cost of making its it systems and non it systems year complaint will be approximately  there can be no assurance  however  that the company will not experience unexpected costs in achieving full year compliance  which could result in a material adverse effect on the company s future results of operations 
the company believes that it will be able to locate alternate sources for any critical goods or services provided by non compliant third parties  if any 
however  the company may not be able to timely develop or implement contingency plans to address those business critical systems and third party relationships which may not be year compliant 
item a 
quantitative and qualitative disclosures about market risk the company owns financial instruments that are sensitive to market risks as part of its investment portfolio 
the investment portfolio is used to preserve the company s capital until it is required to fund operations  including the company s research and development activities 
none of these market risk sensitive instruments are held for trading purposes 
the company does not own derivative financial instruments in its investment portfolio 
interest rate risk the company invests its cash in a variety of financial instruments  principally securities issued by the us government and its agencies  investment grade corporate and money market instruments 
these investments are denominated in us dollars 
these bonds are subject to interest rate risk  and could decline in value if interest rates fluctuate 
the company s investment portfolio includes only marketable securities with active secondary or resale markets to help ensure portfolio liquidity and the company has implemented guidelines limiting the duration of investments 
due to the conservative nature of these instruments  the company does not believe that it has a material exposure to interest rate risk 
page 
